Milestone Pharmaceuticals Inc. APIC, Share-based Payment Arrangement, Recognition and Exercise
Milestone Pharmaceuticals Inc. (MIST) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of -$15.00 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-17.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2021-05-17
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2021-03-31 was -$15.00K.
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-09-30 was -$90.00K.
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-06-30 was -$70.00K.
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2020-03-31 was -$56.00K.
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for fiscal 2019 was $41.00K, a 88.29% decline from fiscal 2018.
- Milestone Pharmaceuticals Inc. apic, share-based payment arrangement, recognition and exercise for fiscal 2018 was $350.00K.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|
| 2021-03-31 | -$15.00K 10-Q · filed 2021-05-17 | |||
| 2020-09-30 | -$90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | -$160.00K derived: sum of 2 quarters · filed 2020-11-13 | -$216.00K 10-Q · filed 2020-11-13 | -$149.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-06-30 | -$70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$126.00K 10-Q · filed 2020-08-12 | -$59.00K derived: sum of 3 quarters · filed 2021-05-17 | -$59.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2020-03-31 | -$56.00K 10-Q · filed 2021-05-17 | $11.00K derived: sum of 2 quarters · filed 2021-05-17 | $11.00K derived: sum of 3 quarters · filed 2021-05-17 | $11.00K derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $67.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $67.00K derived: sum of 2 quarters · filed 2020-11-13 | $67.00K derived: sum of 3 quarters · filed 2020-11-13 | $41.00K 10-K/A · filed 2020-10-23 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-11-13 | -$26.00K 10-Q · filed 2020-11-13 | $356.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$26.00K 10-Q · filed 2019-08-13 | $356.00K derived: sum of 3 quarters · filed 2020-10-23 | $356.00K derived: sum of 4 quarters · filed 2020-10-23 |
| 2019-03-31 | -$26.00K 10-Q · filed 2019-06-19 | $356.00K derived: sum of 2 quarters · filed 2020-10-23 | $356.00K derived: sum of 3 quarters · filed 2020-10-23 | $349.00K derived: sum of 4 quarters · filed 2020-10-23 |
| 2018-12-31 | $382.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-10-23 | $382.00K derived: sum of 2 quarters · filed 2020-10-23 | $375.00K derived: sum of 3 quarters · filed 2020-10-23 | $350.00K 10-K/A · filed 2020-10-23 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$7.00K derived: sum of 2 quarters · filed 2019-11-13 | -$32.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$32.00K 10-Q · filed 2019-08-13 | ||
| 2018-03-31 | -$25.00K 10-Q · filed 2019-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |